News
INTS
3.860
-3.50%
-0.140
Weekly Report: what happened at INTS last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at INTS last week (0415-0419)?
Weekly Report · 04/22 12:28
INTENSITY THERAPEUTICS INC: Current report
Press release · 04/20 01:49
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Benzinga · 04/19 20:05
INTENSITY THERAPEUTICS-GOT NASDAQ LETTER DUE TO RESIGNATION OF DANIEL DONOVAN FROM AUDIT COMMITTEE, CO NOT COMPLIANT WITH NASDAQ LISTING RULE 5605
Reuters · 04/19 20:04
Weekly Report: what happened at INTS last week (0408-0412)?
Weekly Report · 04/15 12:18
Weekly Report: what happened at INTS last week (0401-0405)?
Weekly Report · 04/08 12:24
Weekly Report: what happened at INTS last week (0325-0329)?
Weekly Report · 04/01 12:20
INTS Stock Earnings: Intensity Therapeutics Beats EPS for Q4 2023
Intensity Therapeutics reported earnings per share of -12 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -18 cents. InvestorPlace Earnings is an automated coverage of quarterly earnings reports.
Investorplace · 03/27 03:53
Weekly Report: what happened at INTS last week (0318-0322)?
Weekly Report · 03/25 12:24
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Dow Jones · 03/21 14:16
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benzinga · 03/21 14:06
Weekly Report: what happened at INTS last week (0311-0315)?
Weekly Report · 03/18 12:22
Intensity Therapeutics GAAP EPS of -$1.38
Seeking Alpha · 03/14 21:18
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Research and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for same period in 2022. General and administrative expenses increased due to higher salaries and bonuses. Overall, net loss was $10.5 million for year ended 2023. Cash, cash equivalents and marketable debt securities totaled $14.7 million.
Benzinga · 03/14 20:29
12 Health Care Stocks Moving In Monday's Intraday Session
Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) shares increased by 76.41% during the session. Mesoblast stock rose 22.79% and Graphite Bio stock moved upwards.
Benzinga · 03/11 17:31
Weekly Report: what happened at INTS last week (0304-0308)?
Weekly Report · 03/11 12:16
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NKGen Biotech shares increased by 69.4% to $1.46 during Wednesday's pre-market session. Creative Medical Tech (NASDAQ:CELZ) stock increased by 33.68% in the pre- market session. Aditxt stock rose 13.74% and Vincerx Pharma stock rose 19.34%.
Benzinga · 03/06 13:07
Weekly Report: what happened at INTS last week (0226-0301)?
Weekly Report · 03/04 12:21
Weekly Report: what happened at INTS last week (0219-0223)?
Weekly Report · 02/26 12:41
More
Webull provides a variety of real-time INTS stock news. You can receive the latest news about INTENSITY THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.